ME3 and cancer: Loss of the metabolic gene malic enzyme 2 (ME2) in the SMAD4 locus has been shown to create a cancer-specific metabolic vulnerability upon targeting of its paralogous isoform ME3 in pancreatic ductal adenocarcinoma lacking SMAD4 (35).